Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biotechnol Annu Rev ; 9: 397-417, 2003.
Article in English | MEDLINE | ID: mdl-14650936

ABSTRACT

As the population ages, a dramatic increase in the number of cases of cancer is expected and the need for supportive-care agents, those used to ameliorate some of the side effects of cancer or its treatment, becomes more urgent. At present, supportive-care products are available and new agents are being developed with novel mechanisms of action or modifications of existing agents that improve performance. Because of the urgent need for such products, efficient development is required to deliver useful products to patients as rapidly as possible. This chapter uses actual examples to illustrate the stages of drug development, phase I through phase 3.


Subject(s)
Anemia/drug therapy , Erythropoietin/analogs & derivatives , Erythropoietin/therapeutic use , Fibroblast Growth Factors/therapeutic use , Granulocyte Colony-Stimulating Factor/analogs & derivatives , Granulocyte Colony-Stimulating Factor/therapeutic use , Neoplasms/drug therapy , Neutropenia/drug therapy , Palliative Care/methods , Stomatitis/drug therapy , Anemia/etiology , Antineoplastic Agents/therapeutic use , Clinical Trials as Topic , Darbepoetin alfa , Drug Approval/legislation & jurisprudence , Drug Design , Drug Evaluation/methods , Fibroblast Growth Factor 7 , Filgrastim , Humans , Neoplasms/complications , Neoplasms/therapy , Palliative Care/trends , Polyethylene Glycols , Quality of Life , Recombinant Proteins , Stomatitis/etiology , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...